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Objective: At present, there is growing demand for alternative, or additional, treatments to hormone
replacement therapy for menopause-related hot ﬂashes (HF). Antioxidant supplements have been
recently proposed as possible candidates for this purpose, regardless of the absence of clear evidence in
support of a link between these vasomotor symptoms and oxidative stress (OxS). The aim of our study
was to evaluate the association between HF and OxS serum markers in a large sample of middle-aged
women.
Materials and methods: We conducted a cross-sectional study on 245 perimenopausal and early post-
menopausal women (age 45e60 years). The variables examined were presence of self-reported HF and
levels of 8-iso-prostaglandin F2a, 8-OH-deoxy-20-guanosine, advanced oxidation protein products, total
antioxidant power, uric acid, thiols, and paroxonase-1.
Results: Seventy-six women (31%) reported to suffer from HF (either medium or high intensity). None of
the peripheral markers of OxS examined was found to be signiﬁcantly associated with the presence of HF.
Conclusion: Taken together, our data suggest that systemic OxS might not be implicated with the onset of
the climacteric vasomotor symptoms that most commonly affect women experiencing perimenopause
and early postmenopause.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
At present, the etiology of menopausal vasomotor symptoms
(VS) is not fully understood. However, emerging evidence suggests
that these disturbances may occur within a reduced thermoneutral
zone caused by an ineffective interaction between norepinephrine
and 17 b-estradiol (E2)-regulated a2-adrenergic receptors [1,2].
Several studies have also indicated that the occurrence of VS mayical and Specialist Surgical
ular Biology and Genetics,
taly. Tel.: þ39 0532 455444,
bstetrics & Gynecology. Publishedrepresent not merely an effect of estrogen deﬁciency that can
impair the quality of life, but also an early indicator of cardiovas-
cular disease (CVD) risk [3,4]. Indeed, the presence and severity of
night sweats, and, in particular, hot ﬂashes (HF) is correlated with a
proatherogenic condition featuring high blood pressure and
cholesterol levels, as well as impaired endothelial function [3,4].
These ﬁndings have been interpreted by some authors as a clue of
an implication of oxidative stress (OxS) in the etiology of these
climacteric disturbances [5e7]. Indeed, it is nowwidely recognized
that OxS plays a key role in all the stages of atherogenesis, from
endothelial dysfunction to atheromatous plaque formation and
rupture [8]. Furthermore, OxS is known as one of the most
important contributors to the increased risk of CVD associated with
menopausal transition [9]. Indeed, postmenopausal women are
regarded as more vulnerable to OxS-related damage than womenby Elsevier Taiwan LLC. All rights reserved.
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is mutually associated with an increase in OxS) but also because of
lower levels of E2, which is believed to act as an antioxidant
[10e12].
On these bases, the aim of the present study was to investigate
the association between HF and serum markers of both OxS-
induced oxidative damage and antioxidant levels, in a sample of
245 healthy, nonobese women of perimenopausal and post-
menopausal status.
Materials and methods
The present study included a subset of women enrolled in an
observational research study by the Menopause and Osteoporosis
Centre of the University of Ferrara (Ferrara, Italy), aimed at evalu-
ating the physical and physiological correlates of OxS in women.
These studies were undertaken within the framework of a protocol
approved by the Medical School Ethics Committee, and in accor-
dance with the Declaration of Helsinki (World Medical Association,
http://www.wma.net), and the guidelines for Good Clinical Practice
(EuropeanMedicines Agency, http://www.ema.europa.eu). Women
were recruited upon signing an informed consent. Eligible partici-
pants were Caucasian women aged 45e60 years in perimenopause
and early postmenopause (stage 1b or 2, assessed according to the
Stages of Reproductive Aging Workshop bleeding criteria [13]). In
particular, women in perimenopause experienced an increased and
persistent variability of menstrual cycle length. Women reporting
periods of amenorrhea longer than 11 months were classiﬁed as
postmenopausal. Additionally, to conﬁrm the assignment of
menopausal status, we determined the blood levels of follicle-
stimulating hormone and E2 for each woman, by using commer-
cially available chemiluminescent microparticle immunoassays
(Architect, Abbott Park, IL, USA), as previously described [14].
Exclusion criteria were factors known to inﬂuence OxS such as, the
use of exogenous sexual hormones (including vaginal estrogens),
dietary supplementation with nutritional antioxidants, vegetarian
or vegan diet, and the diagnosis of a chronic disease (e.g., diabetes
and hypertension).
Vasomotor symptoms
The presence of HF was assessed via a questionnaire at each
visit and on the same day as the blood draw. At the beginning of
the study, two questions were asked: (1) did the woman experi-
ence any HF in the 2 weeks prior to her visit? (2) If so, did she
experience HF that can be classiﬁed as moderate to severe (i.e.,
having HF for more than 5 days/wk, with an average of more than
4 HF/d, and with at least six or more HF in 1 day)? [4]. Based on the
responses to these questions, a dichotomous variable was created
as follows:
 Absence of HF:
- if the answer was “No” to question (1)
- if the answer was “Yes” to question (1) but “No” to question (2)
 Presence of HF:
- if the answer was “Yes” to both questions (1) and (2)
Women who were enrolled within the past two years of the
study (n ¼ 85) were additionally evaluated for VS using the Greene
climacteric scale [15]. This scale is composed of 21 items that es-
timate VS, anxiety, depression, somatic symptoms, and sexuality.
Each item is rated according to its severity on a 4-point scale: not at
all (0), a little (1), quite a bit (2), and extremely (3). In this study, we
only evaluated the two items (frequency of HF and sweating at
night) that are used to calculate the subscore for VS (range 0e6).Biochemical assays
Blood and urine were collected after overnight fast. Serum
samples were obtained from blood by centrifugation (4650g for 20
minutes) and stored at 80C until analysis.
The concentration of free 8-iso-prostaglandin F2a, (8-isoPGF2a)
was assessed in urine by enzyme immunoassay (Cayman Chemical,
Ann Arbor, MI, USA) following the manufacturer's protocol. Butyl-
ated hydroxytoluenewas added to each aliquot (ﬁnal concentration
0.005%) to prevent oxidation during processing.
Urine levels of 8-OH-deoxy-20-guanosine (8-OH-dG) were
measured by competitive immune-enzymatic assay (StressMarq
Biosciences Inc., Victoria, BC, Canada). The concentrations of 8-
isoPGF2a and 8-OH-dG concentration were normalized to urinary
creatinine concentration, and expressed as ng/mg creatinine.
The serum concentration (expressed as mM) of advanced
oxidation protein products (AOPP) was determined by spectro-
photometric detection according to Capeillere-Blandin et al [16].
The collective contribution of nonenzymatic antioxidants (vi-
tamins A, E, and C, uric acid, etc.) was measured by serum total
antioxidant power (TAP) by ferric reduction/antioxidant power
(FRAP) method [17] and the results of this colorimetric assay were
expressed as FRAP units, where 1 FRAP unit corresponds to the
reduction of 100mM of Fe3þ reduced to Fe2þ in 6 minutes.
The concentration of serum uric acid (mM) was determined by
direct colorimetric enzymatic method in which uric acid was
oxidized by uricase coupled with peroxidase [18].
Total concentration of serum thiols (mM) was determined by
colorimetric DTNB-based assay as described by Hu [19]. The mea-
surement of serum paraoxonase-1 (PON-1) basal activity was per-
formed by using paraoxon as substrate as described elsewhere [20].
PON-1 basal activity was expressed as U/mL, where one unit is
equivalent to 1 nmol of paraoxon hydrolysed/min.
Statistical analysis
SPSS 17.00 forWindows (SPSS Inc., Chicago, IL, USA)was used for
statistical analysis. Unpaired Student t test (for normal variables)
andManneWhitney U test (for non-normal variables) were used to
identify signiﬁcant differences in the two sample groups consid-
ered. The Chi-square test was used to compare differences in cate-
gorical variables. Spearman correlation analysis was implemented
for checking if ordinal variables (Greene climacteric subscale for VS)
were related to continuous variables (levels of OxSmarkers). A two-
tailed p < 0.05 was considered statistically signiﬁcant.
Results
The main characteristics, as well as the mean serum levels of
OxS markers, of the enrolled women subdivided according to
presence (n ¼ 76, 31%) or absence (n ¼ 169, 69%) of HF are reported
in Table 1. Based on these results, it is clear that the two sample
subgroups are very similar in age, years since menopause, physical
features, and the levels of sex hormones. Likewise, ManneWhitney
U test showed that none of the OxS markers examined was
signiﬁcantly different between the two given subgroups.
In line with the aforementioned results, there was no signiﬁcant
correlation between OxS markers and VS score obtained by the
Greene climacteric VS subscale, in the subset of 85 women who
were enrolled in the last two years of the study (Table 2).
Discussion
The assessment of OxS in living organisms represents a crucial
analytical challenge, mainly because the direct determination of
Table 1
General characteristics and oxidative stress markers of the study participants.
Characteristics All women (n ¼ 245) Presence of hot ﬂashes p
Absent (n ¼ 169) Present (n ¼ 76)
Age (y) 53.3 ± 4.2 53.4 ± 4.2 53.5 ± 4.3 0.879
Time since menopause (y) 2.4 (1.0e4.4) 2.4 (1.0e4.0) 2.2 (1.0e5.8) 0.285
Age at menarche (y) 12.0 (11.0e13.0) 12.0 (11.0e13.0) 12.0 (11.0e13.2) 0.258
E2 (pg/mL) 10.0 (6.0e28.5) 11.0 (6.0e28.0) 8.0 (6.0e39.0) 0.251
FSH (mUI/mL) 69.5 ± 30.6 66.4 ± 30.2 72.1 ± 25.7 0.090
BMI (kg/m2) 24.9 ± 3.6 25.1 ± 3.8 24.9 ± 3.6 0.356
Waist circumference (cm) 85.1 ± 10.4 85.5 ± 9.8 84.1 ± 11.6 0.258
Hypertension (%) 11.3 13.0 7.4 0.221
Smokers (%) 13.9 12.3 17.6 0.284
Oxidative stress markers
8-isoPGF2a (ng/mg creatinine) 1.21 ± 0.10 1.19 ± 0.12 1.26 ± 1.10 0.752
8-OH-dG (ng/mg creatinine) 164.0 ± 100.9 159.0 ± 97.4 174.1 ± 109.4 0.651
AOPP (mM) 221 (188e280) 224 (187e285) 217 (187e266) 0.416
TAP (FRAP unit) 709.6 ± 153.9 711.9 ± 157.0 704.7 ± 148.1 0.755
Uric acid (mM) 80 (46e105) 79 (59e105) 83 (63e111) 0.272
Thiols (mM) 209 (162e233) 206 (161e234) 216 (179e231) 0.828
PON-1 (U/L) 106 (61e177) 105 (60e173) 117 (59e196) 0.923
Data are expressed as mean ± standard deviation/median (interquartile range) when the variable was normally/not normally distributed, respectively.
8-isoPGF2a ¼ 8-iso-prostaglandin F2a; 8-OH-dG ¼ 8-OH-deoxy-20-guanosine; AOPP ¼ advanced oxidation protein products; BMI ¼ body mass index; E2 ¼ 17b eestradiol;
FSH ¼ follicle stimulating hormone; PON-1 ¼ paroxonase 1; TAP ¼ total antioxidant power.
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impracticable in large-scale population studies [21]. The only
feasible approach is the indirect assessment of these species
through the quantiﬁcation of by-products of oxidative damage to-
wards biomolecules such as lipids, DNA, and proteins [21,22].
Among the potential markers that have been identiﬁed so far, uri-
nary 8-isoPGF2a and 8-OH-dG, which are indicators of lipid and
DNA oxidative challenge, respectively, have proven to be the most
reliable [22]. However, thus far, there has been no widespread
agreement onwhichmarker should bemeasured for assessing OxS-
induced protein damage. The recently described AOPP, have
emerged as promising markers of this type of molecular injury,
because of their strong associationwith CVD and several other OxS-
related disorders [23].
We thoroughly considered the aforementioned methodological
issues in the selection of markers to employ in the present study,
which aimed to investigate the interplay between OxS and HF. In
study this, we compared the levels of urinary 8-isoPGF2a and 8-
OH-dG, along with serum AOPP, between perimenopausal and
early postmenopausal women with or without complaints of HF.
Our analyses indicate that there is no signiﬁcant difference in OxS
pattern between these two groups (Table 1), and therefore, no as-
sociation between HF and systemic OxS.
Our negative results are in apparent contradiction to those of
other studies suggesting that menopause, as well as relatedTable 2
Relationship between oxidative stress markers and Greene climacteric subscale for







Uric acid 0.027 0.821
Thiols 0.046 0.713
PON-1 0.070 0.609
8-isoPGF2a ¼ 8-iso-prostaglandin F2a; 8-OH-dG ¼ 8-OH-deoxy-20-guanosine;
AOPP ¼ advanced oxidation protein products; PON-1 ¼ paraoxonase 1; TAP ¼ total
antioxidant power.
a Frequency of women according to Greene vasomotor symptoms score:
Score ¼ 0, n ¼ 34; score ¼ 1, n ¼ 19; score ¼ 2, n ¼ 9; score ¼ 3, n ¼ 7; score ¼ 4,
n ¼ 7; score ¼ 5, n ¼ 4; score ¼ 6, n ¼ 5.disturbances and diseases, might be linked to the accumulation of
oxidative damage [5,24]. In reality, it is worth noting that the in vivo
antioxidant effectiveness of endogen E2, which is the conceptual
basis in support of this association [5,10e12], is still far from being
deﬁnitely demonstrated, mainly because of the controversial
epidemiological data on this topic. Indeed, while some large studies
showed increased levels of urinary 8-OH-dG in postmenopausal
women compared to women of reproductive age [24,25], other
investigators did not observe any signiﬁcant differences in the
levels of the more sensitive urinary 8-isoPGF2a [26,27] (lipids are
more sensitive to a rise in OxS than DNA [22]) or AOPP [28].
Moreover, mixed results were obtained using different markers of
lipoperoxidation, such as serum malondialdehyde or lipid hydro-
peroxides, which, depending on the study, showed higher [29],
unvaried [14,30], or lower levels of oxidation [28], in post-
menopausal compared to premenopausal women. The well-
documented low speciﬁcity and sensitivity of these indexes
(especially when they are not measured by using a ﬂuorimetric-
high-performance liquid chromatography approach [22]), the lack
of consideration of potential confounders of statistical analysis
(including, but not limited to, body fat parameters [30,31]) as well
as the limited sample size, might explain the high level of incon-
sistency in these results.
Similar methodological and study design limitations, as well as
differences in sample characteristics, might also account for the
discrepancy between our results and those of the study by Leal et al
[6] that examined the correlation between HF and OxS. In Leal
et al's [6] work, the lipoperoxide levels (measured colorimetrically)
positively correlated with the presence of HF in a small (n ¼ 45)
sample of postmenopausal women. Moreover, at variance with this
investigation, in our study women with HF were not deﬁcient in
either dietary (collectively measured by total antioxidant power) or
endogenous (thiols, uric acid, and PON-1) antioxidants, when
compared to those without these symptoms. This ﬁnding is in line
with observations from other studies exploring the effects of
antioxidant supplementation [32e35] on the frequency and
severity of HF. Notably, the amelioration of ﬂushing intensity after
treatment with a-tocopherol reported in one of these studies [32]
has been attributed to the nonantioxidant actions of this vitamin,
in particular, the ability to regulate the hypothalamic release of
norepinephrine, which, in turn, plays a role in core body temper-
ature control.
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these symptoms cannot be measured objectively but only by self-
reported data. At the start, our study was further affected by a less
comprehensive estimation of VS mostly because of the lack of eval-
uation of the frequency of night sweats. In an attempt to overcome
this drawback, VS ofwomenenrolledduring the last part of the study
protocol of the studywere evaluated by Greene VS subscale (1 of the
5 subscales of the Greene climacteric scale). In line with the data
obtained with the dichotomous variable for HF, no signiﬁcant cor-
relations emerged between OxS markers and, thus, VS score
(Table 2). Speciﬁc limitations of our study lied in its cross-sectional
design, which prevents us from reaching a deﬁnitive appreciation
of a link among factors considered in the analysis (a longitudinal
approach is more valuable for this purpose), and the unequal size of
the subgroups, which could affect the reliability of statistical out-
comes. However, the latter limitation was, at least partially, over-
come by the use of a nonparametric test such as theManneWhitney
U test, which is regarded as themost appropriate tool for the analysis
of difference between groups with this feature. Finally, it is worth
pointing out that the absence of a universal biomarker for OxS
detection remarkably affects the reliability of our results.
Conclusion
To the best of our knowledge, this study is among the ﬁrst to
investigate the potential interaction between HF and OxS in a,
relatively, large sample of healthy perimenopausal and early post-
menopasual women. Globally taken, our data did not support the
existence of an association between these typical climacteric
symptoms and the pathophysiological condition. However, we are
aware that further investigations of longitudinal design are needed
to conﬁrm our results.
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